The still-recruiting NCT03867682 trial investigates the maximum tolerated dose and remission state in adult relapsed/refractory AML receiving a radiolabeled anti-CD33 conjugate (225- Ac-Lintuzumab) + VEN. Here, CD33 is linked to acute myeloid leukemia.